9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Estimated reading time: < 1 min

Condition: Advanced Cancer

Estimated Enrollment: 1350

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Objective Response Rate (ORR),  ,  ,

Interventions: pembrolizumab,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: August 28, 2023

Completion Date: August 28, 2023

Last  Posted Date: July 19, 2019

Location: Call for Information (Investigational Site 0018), Duarte, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT02628067

Was this article helpful?
Dislike 0